EP1154801A4 - INTEGRATION OF TRANSPLANTED NEURAL PRECELLER CELLS IN NEURAL TISSUE OF IMMEDIATE AND TIRE DYSTROCE RECEIVERS - Google Patents

INTEGRATION OF TRANSPLANTED NEURAL PRECELLER CELLS IN NEURAL TISSUE OF IMMEDIATE AND TIRE DYSTROCE RECEIVERS

Info

Publication number
EP1154801A4
EP1154801A4 EP00907260A EP00907260A EP1154801A4 EP 1154801 A4 EP1154801 A4 EP 1154801A4 EP 00907260 A EP00907260 A EP 00907260A EP 00907260 A EP00907260 A EP 00907260A EP 1154801 A4 EP1154801 A4 EP 1154801A4
Authority
EP
European Patent Office
Prior art keywords
neural
preceller
dystroce
receivers
tire
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00907260A
Other languages
German (de)
French (fr)
Other versions
EP1154801A1 (en
Inventor
Michael J Young
Fred H Gage
Jasodhara Ray
Simon J Whiteley
Henry Klassen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Schepens Eye Research Institute Inc
Salk Institute for Biological Studies
Original Assignee
Schepens Eye Research Institute Inc
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schepens Eye Research Institute Inc, Salk Institute for Biological Studies filed Critical Schepens Eye Research Institute Inc
Publication of EP1154801A1 publication Critical patent/EP1154801A1/en
Publication of EP1154801A4 publication Critical patent/EP1154801A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
EP00907260A 1999-02-11 2000-02-11 INTEGRATION OF TRANSPLANTED NEURAL PRECELLER CELLS IN NEURAL TISSUE OF IMMEDIATE AND TIRE DYSTROCE RECEIVERS Withdrawn EP1154801A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11964299P 1999-02-11 1999-02-11
US119642P 1999-02-11
PCT/US2000/003534 WO2000047238A1 (en) 1999-02-11 2000-02-11 Integration of transplanted neural progenitor cells into neural tissue of immature and mature dystrophic recipients

Publications (2)

Publication Number Publication Date
EP1154801A1 EP1154801A1 (en) 2001-11-21
EP1154801A4 true EP1154801A4 (en) 2002-08-21

Family

ID=22385498

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00907260A Withdrawn EP1154801A4 (en) 1999-02-11 2000-02-11 INTEGRATION OF TRANSPLANTED NEURAL PRECELLER CELLS IN NEURAL TISSUE OF IMMEDIATE AND TIRE DYSTROCE RECEIVERS

Country Status (5)

Country Link
EP (1) EP1154801A4 (en)
JP (1) JP2002536423A (en)
AU (1) AU2878400A (en)
CA (1) CA2362476A1 (en)
WO (1) WO2000047238A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002230669A1 (en) * 2000-11-06 2002-05-15 The Salk Institute For Biological Studies Postmortem stem cells
JP2006506970A (en) 2002-07-12 2006-03-02 ユニバーシティ オブ ワシントン Methods and systems for extended in vitro culture of neurons
DE60326003D1 (en) * 2002-12-02 2009-03-12 Anges Mg Inc TER USE OF THE HEPATOCYTE GROWTH FACTOR
US9061017B2 (en) 2006-05-03 2015-06-23 The Schepens Eye Research Institute, Inc. Isolation and therapeutic application of adult retinal stem cells collected from extra-retinal tissues
WO2007130060A2 (en) 2006-05-03 2007-11-15 Schepens Eye Research Isolation and therapeutic application of adult retinal stem cells collected from extra-retinal tissues
JO3626B1 (en) * 2012-02-23 2020-08-27 Merial Inc Topical formulations containing fipronil and permethrin and how to use them

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GAGE F H ET AL: "SURVIVAL AND DIFFERENTIATION OF ADULT NEURONAL PROGENITOR CELLS TRANSPLANTED TO THE ADULT BRAIN", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 92, 1 December 1995 (1995-12-01), pages 11879 - 11883, XP002034681, ISSN: 0027-8424 *
See also references of WO0047238A1 *
SUHONEN JAANA O ET AL: "Differentiation of adult hippocampus-derived progenitors into olfactory neurons in vivo.", NATURE (LONDON), vol. 383, no. 6601, 1996, pages 624 - 627, XP002203051, ISSN: 0028-0836 *
TAKAHASHI M ET AL: "WIDESPREAD INTEGRATION AND SURVIVAL OF ADULT-DERIVED NEURAL PROGENITOR CELLS IN THE DEVELOPING OPTIC RETINA", MOLECULAR AND CELLULAR NEUROSCIENCES, SAN DIEGO, US, vol. 12, December 1998 (1998-12-01), pages 340 - 348, XP002926797, ISSN: 1044-7431 *

Also Published As

Publication number Publication date
EP1154801A1 (en) 2001-11-21
JP2002536423A (en) 2002-10-29
WO2000047238A1 (en) 2000-08-17
WO2000047238A9 (en) 2001-07-26
CA2362476A1 (en) 2000-08-17
AU2878400A (en) 2000-08-29

Similar Documents

Publication Publication Date Title
ATE349428T1 (en) PROSTAGLAND INAGONISTS AND THEIR USE IN THE TREATMENT OF BONE DISEASES
ATE229815T1 (en) IN VITRO METHODS AND USE OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INNER EAR HAIR CELLS
DE69841509D1 (en) LEKTRODENFOMSTÜCK AND ELECTROCHEMICAL ELEMENTS
EE200100480A (en) Xenon for use in the treatment of nerve poisoning
DE59603216D1 (en) Esterquats and their use for the production of surface-active agents, in particular for hair and body care
EP1257282A4 (en) PANCREATIC STEM CELLS AND THEIR USE IN TRANSPLANTATION
DE60004169D1 (en) ARRANGEMENT OF ELECTROCHEMICAL CELLS AND BOARD
AU7375100A (en) Water absorbent keratin and gel formed therefrom
DE60017894D1 (en) DIAMINOTHIAZOLE AND ITS USE IN THE INHIBITION OF PROTEIN KINASES
DE60233265D1 (en) 5-Sulphinyl-4H-1,2,4-triazole derivatives and their use in the treatment of somatostatin-mediated diseases
ID20600A (en) GENETIC MODIFIED CELLS AND ITS USE IN PROFILACTIC OR DISEASE THERAPY
IS5504A (en) Composition active in the treatment of impotence
ATE234840T1 (en) 1-AMINOTRIAZOLO 4,3-A QUINAZOLIN-5-ONE AND/OR - THIONE INHIBITORS OF PHOSPHODIESTERASES IV
DE60032886D1 (en) USE AND PREPARATION OF POLYPROPYLENE
DE60017133D1 (en) Naphthoquinone derivatives and their use in the treatment and control of tuberculosis
DE69806071D1 (en) ACTIVE OXYGEN REMOVING COMPOSITIONS AND THEIR USE IN PACKAGING
ATE323685T1 (en) DIHYDROBENZODIAZEPINES AND THEIR USE IN THE TREATMENT OF DYSLIPIDAEMIA
EP1154801A4 (en) INTEGRATION OF TRANSPLANTED NEURAL PRECELLER CELLS IN NEURAL TISSUE OF IMMEDIATE AND TIRE DYSTROCE RECEIVERS
AU8821901A (en) Stimulation of cellular regeneration and differentiation in the inner ear
AU2001288219A1 (en) Stimulation of cellular regeneration and differentiation in the inner ear
AR027832A1 (en) TREATMENT METHODS AND TRAFFIC METHODS OF PHARMACOS
EP0904074A4 (en) Use of cell membrane permeants in the treatment of cellular proliferative diseases
WO1999045103A3 (en) Human spinal cord cell lines and methods of use therefor
DE60022697D1 (en) Quinoxaline resin for use as active material in battery and capacitor
NO20010044L (en) Use of texaphyrins in macrophage-mediated diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010911

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20020708

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030902